Chongqing Changshou Manufacturing Site
As the small molecule drug substance GMP facilities, we consists of Production, Technology, Quality, EHS, Supply chain management and Equipment departments.
1 Fine Chemical Zone, Changshou District, Chongqing, China
2005Founded
It is a flagship API plant of Porton.
206,198m2Area
There are 11 workshops under operation at the Changshou site, operating 24 hours a day, 7 days a week.
834.3m3Total Capacity
The reactor volume ranges from 5L to 10,000L, delivering products from kilograms to metric tons.
Capabilities
- Temperature Range from -20℃ to 120℃/li>
- Cryogenic down to -90℃/li>
- High Temperature up to 200℃
- Hydrogenation up to 60 bar
- High Vacuum Thin Film Evaporator
- Column Chromatograph
- Flow Manufacturing
- Distillation Column for Liquid Product Purification
- OEB 4 Compound Handling with ECM
Services
Small Molecule
Small Molecule
Porton offers efficient, flexible, and high-quality solutions for custom development and production of small molecule APIs, as well as technical services throughout the entire lifecycle from pre-clinical to commercial stages to our worldwide partners.
One Porton One Quality
Track Records of Inspections and Audits
We engage in implementing quality management throughout the lifecycle of the product from R&D, production, control, to release. Directed by customer needs, the Changshou site has passed inspections conducted by NMPA, USFDA, PMDA, WHO, and EMA and will maintain its quality commitment of "System compliance, continuous improvement, and customer orientation."
SME Teams
In the drug lifecycle, drug development, production, and regulation are highly complex and specialized. Porton has established a professional SME team that has accumulated profound knowledge and experience in technology, regulations, and business. This ensures that Porton remains competitive in a highly regulated market, delivering efficient and compliant solutions and services.
Case Studies
More
Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost
Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development
Agile and Fast：Enabling Rapid Market Launch of Innovative Drugs from Preclinical to Commercialization in 18 Months
News
MoreNews2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
More
News2024-12-19
Porton Newsletter | Q4 2024 Recap
More
News2024-12-06
Porton is thrilled to announce the launch of its newly redesigned official website
More
News2024-10-14
Driving innovation and excellence in the CDMO industry, Porton at 2024 CPHI Europe
More
